Vaxil Bio Company
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner.
Technology:
Peptides and Proteins
Industry:
Peptides and Proteins
Headquarters:
Toronto, Ontario, Canada
Founded Date:
2007-01-01
Employees Number:
1-10
Funding Status:
IPO
Total Funding:
32500000
Estimated Revenue:
Less than $1M
Register and Claim Ownership